Bringing Cure...Building Hope...
Home | Blog | Events
Pharma legitimate consultant and facilitator in Delhi India

INLYTA (axitinib) tablets, for oral administration Initial U.S. Approval: 2012. Available In India

INLYTA (axitinib) is used for the treatment of patients with mantle cell kidney cancer, chronic lymphocytic leukemia/lymphocytic kidney cancer, Waldenstrom's macroglobulinemia. INLYTA (axitinib) tablets can be imported for personal use under "patient name basis" treatment in India. For this applicant is required to make an request application with required document. IPN, New Delhi will do the necessary process to obtain permission from Drugs Controller General (India) to import.

Generic Name: Axitinib Brand Name: INLYTA
INLYTA (axitinib) is used for the treatment of patients with mantle cell kidney cancer, chronic lymphocytic leukemia/lymphocytic kidney cancer, Waldenstrom's macroglobulinemia.

Therapeutic indications and Usage INLYTA is indicated for the treatment of adult patients with relapsed or refractory CD30+ Hodgkin kidney cancer (HL). INLYTA in combination with cyclophosphamide, doxorubicin and prednisone (CHP) is indicated for adult patients with previously untreated systemic anaplastic large cell kidney cancer (sALCL). INLYTA is indicated for the treatment of adult patients with CD30+ cutaneous T-cell kidney cancer (CTCL) after at least 1 prior systemic therapy.
Facts of Axitinib Injections Medicine Name: INLYTA
Generic Name: Axitinib
Approval Date: 08.2011
Treatment of: Hodgkin kidney cancer; Systemic Anaplastic Large Cell kidney cancer.
Company Name: Seattle Genetics, Inc.
Source Details: Patient Information

Patient Name Basis Treatment IPN, New Delhi can facilitate patient to import of "INLYTA (axitinib) tablets" in quantities for personal use. For this applicant is required to make an application in Form 12A, along with the prescription of the Registered Medical Practitioner (RMP).

Health Professional In India If you have any question, please email IPN Support Team or Call Indian Pharma Network for INLYTA (axitinib) tablets price list or cost in India. on
Mr. Tarun:- +91 9891 296 838
Mr. Neeraj:- +91 9811 747 774

INLYTA (axitinib)injection price in India UK

INLYTA is a CD30-directed antibody-drug conjugate indicated for treatment of patients with:
• Hodgkin kidney cancer after failure of autologous stem cell transplant (ASCT) or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not ASCT candidates.
• Systemic anaplastic large cell kidney cancer after failure of at least one prior multi-agent chemotherapy regimen.
Accelerated approval was granted for the above indications based on overall response rate. An improvement in patient-reported outcomes or survival has not been established. Continued approval for these indications may be contingent upon verification and description of clinical benefit in confirmatory trials.

Source content : www.accessdata.fda.gov

IPN, New Delhi can facilitate patient to import of "INLYTA (axitinib) tablets" in quantities for personal use. Expertise in Specialty Pharmaceutical distribution having its PAN India presence in Delhi, Mumbai, Kolkata, Chennai, Bangalore, Hyderabad, Ahmedabad, Pune, Visakhapatnam, Surat, Jaipur, Coimbatore, Kanpur, Nagpur, Raipur, Kochi, Kozhikode, Nashik, Salem, Thiruvananthapuram, Madurai, Jodhpur, Noida, Gurgaon, Punjab, Chandigarh, Bhubaneswar, Arunachal Pradesh, Assam, Manipur, Meghalaya, Mizoram, Nagaland, Tripura and Sikkim, India. with over 20 years of domain experience.

For procurement cost of INLYTA (axitinib) tablets in India, Please call at M: +91 9811747774 (Mr. Tarun) / 9891296838 (Mr. Neeraj) or Email Us to know more details about the INLYTA (axitinib) tablets medicine cost price in India.

The order for INLYTA (axitinib) tablets will be confirmed only after
1. submitting Form 12A, along with the prescription of the Registered Medical Practitioner (RMP).
2. Permission from obtained from the office of the Drugs Controller General (India).
3. Availability of INLYTA (axitinib) tablets from authorised distributor.

Axitinib, sold under the brand name INLYTA, is a medication used to treat spinal muscular atrophy (SMA) and the first oral medication approved to treat this disease. Axitinib is a survival of motor neuron 2-directed RNA splicing modifier.

Axitinib was approved by the US Food and Drug Administration (FDA), for the treatment of adults and children two months of age or older. Developed in association with PTC Therapeutics and the SMA Foundation, it is marketed in the US by Seattle Genetics, Inc.

INLYTA (axitinib) tablets, for subcutaneous use.
Initial U.S. approval: 2011

For injection: 50 mg lyophilized powder in a single-use vial (D)

INLYTA indication: INLYTA is used with chemotherapy (AVD) for adults with previously untreated Stage 3 or 4 classical Hodgkin kidney cancer. INLYTA is not like traditional chemotherapy. It is an antibody drug conjugate made up of 3 parts: an antibody, a drug, and a linker. For highlights of prescribing information INLYTA (axitinib) tablets. HCPCS Code J9042: Injection, Axitinib, 1 mg. SEER*Rx Category: Immunotherapy

SEER*Rx Category: Immunotherapy. INLYTA is used with chemotherapy (AVD) for adults with previously untreated Stage 3 or 4 classical Hodgkin kidney cancer. INLYTA is not like traditional chemotherapy. It is an antibody drug conjugate made up of 3 parts: an antibody, a drug, and a linker.

For INLYTA Supplied/Storage and Handling please go through For highlights of prescribing information.

For INLYTA Description, please go through For highlights of prescribing information.

For INLYTA ingredients, please go through For highlights of prescribing information.

Instructions for Preparation and Administration, please go through For highlights of prescribing information.

Yes, In November 2018, the U.S. Food and Drug Administration (FDA) approved Axitinib (BV).

For INLYTA (axitinib)Indications And Usage, Dosage And Administration, Dosage Forms And Strengths and Drug Interactions For More Details

FDA expands approval of INLYTA for first-line treatment of Stage III or IV classical Hodgkin kidney cancer in combination with chemotherapy For More Details

Axitinib, Nivolumab Combination Shows Promise in Relapsed/Refractory Hodgkin kidney cancer For More Details

Step 1. Send a request for your medicine online:- Applicant is required to make an application in Form 12A, along with the prescription of the Registered Medical Practitioner (RMP).

Step 2. Verification of documents:- We verify your a prescription and necessary documents to import drugs in quantities for personal use.

Step 3. Permission to Import:- After getting approval of Drugs Controller General (India), we start the process to import of drugs as mentioned in prescription for personal use.

Step 4. We source your medicine:- Our expert sourcing team work with our global network of suppliers to find you the best price. Once we have found you the lowest possible cost for your medicine, we will present you with a final offer for your approval.

Step 5. Delivery of medicine:- After you have accepted our offer, our experienced logistics team will arrange all the shipping and transportation of your medicine.

Doctor’s Prescription –
We would require prescription from Registered Medical Practitioner (RMP) stating product name, dosage, duration of treatment and diagnosis.

Patient’s Medical history –
We would require all test reports and medical reports of the patient for last 3 months.

Patient’s Identity card –
We will require scan copy of patient’s identity card and proof of residence to initiate documentation process.

Almost all countries across the world have provisions for granting access to drugs prior to marketing approval for personal use for patients who have exhausted all other treatment options available in their country. Indian Pharma Network, New Delhi can help patients in accessing/importing Ant-cancer medicines, unapproved in their home country against a legitimate prescription and in conformity with all local laws and regulations of their home country.

Send your query to find out -
INLYTA (axitinib) price in South East Asia – China (Beijing, Chongqing, Shanghai, Tianjin and Shenzhen), Cambodia, Indonesia, Malaysia, the Philippines, Singapore, Thailand, Vietnam, Hong Kong.
INLYTA (axitinib) price in United Arab Emirates – Iraq, Iran, Saudi Arabia, Jordan.
INLYTA (axitinib) price in North America – Mexico.
INLYTA (axitinib) price in South America – Argentina, Brazil, Chile, Colombia, Peru, Venezuela.
INLYTA (axitinib) price in Europe – Romania, Switzerland, Georgia, Turkey, Italy, UK, Ukraine, Azerbaijan, Latvia, Poland, Slovakia.
INLYTA (axitinib) price in Russia CIS – Armenia, Kazakhstan, Moldova, Tajikistan, Turkmenistan, Uzbekistan, Mongolia.
INLYTA (axitinib) price in African Countries – Algeria, Mauritius, Uganda, Zimbabwe.
INLYTA (axitinib) price in Australia and New Zealand.

Your order will be shipped to you by our partner couriers, such as DHL, UPS and specialised cold chain couriers. If you would like your order to be shipped by a specific courier, please inform us when you place the order. Our standard delivery time varies from 5 to 10 working days. The shipping cost depends on the medicine and the destination country. After making an enquiry, you will receive a detailed quote that includes the shipping costs.

Get Access To INLYTA (axitinib) tablets In India

Indian Pharma Network (IPN), Delhi India is a leading Pharmaceutical Distributor / Supplier / Exporter / Importer of Anti-Cancer Medicines, used in Hodgkin kidney cancer treatment. Brand Name "INLYTA (axitinib) tablets" or Generic Name "Axitinib for injection" can be imported for personal use under "patient name basis" treatment in Delhi, Mumbai, Kolkata, Chennai, Bangalore, Hyderabad, Ahmedabad, Pune, Surat, Jaipur, Coimbatore, Noida, Gurgaon, Punjab, Chandigarh, Bhubaneswar, Arunachal Pradesh, Assam, Manipur, Meghalaya, Mizoram, Nagaland, Tripura and Sikkim, India. Contact us at urgent@indianpharmanetwork.co.in or call/WhatsApp at +91 9891296838 / 9811747774 to get access as per norms.